Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Roche Holding AG | 189 |
| 2 | Gilead Sciences Inc | 93 |
| 3 | Cincinnati Children's Hospital Medical Center | 25 |
| 4 | The University of Texas System | 23 |
| 5 | Government of the United States of America | 22 |
| 6 | University of North Carolina System | 21 |
| 7 | Guardant Health Inc | 16 |
| 8 | Johnson and Johnson | 16 |
| 9 | Bristol Myers Squibb Co | 14 |
| 10 | NeoGenomics Inc | 14 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 888 |
| 2 | A61P | Therapeutic activity (drug indications) | 861 |
| 3 | C07K | Peptides | 354 |
| 4 | C07D | Heterocyclic compounds | 320 |
| 5 | C12N | Microorganisms, enzymes | 198 |
| 6 | C12Q | Measuring/testing involving enzymes | 193 |
| 7 | G01N | Investigating / analysing materials | 146 |
| 8 | G16B | 142 | |
| 9 | G16H | Digital health, healthcare informatics | 92 |
| 10 | Y02A | Climate change adaptation | 53 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Simultaneous spatio-temporal measurement of gene expression and cellular activity | 2023 | 10X Genomics Inc | 58 |
| Simultaneous spatio-temporal measurement of gene expression and cellular activity | 2024 | 10X Genomics Inc | 19 |
| TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | 2022 | Roche Holding AG | 31 |
| Substituted pyrazolo [1,5-a] pyrazine compound as RET kinase inhibitor | 2019 | Pfizer Inc | 22 |
| Plasma-based detection of Anaplastic Lymphoma Kinase (ALK) nucleic acids and ALK fusion transcripts and their use in cancer diagnosis and treatment | 2019 | Bio Techne Corp | 22 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 39 |
| 2017 | 41 |
| 2018 | 57 |
| 2019 | 45 |
| 2020 | 54 |
| 2021 | 81 |
| 2022 | 45 |
| 2023 | 52 |
| 2024 | 44 |
| 2025 | 24 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Peter N. Morcos | Roche (United States) | 19 |
| 2 | Makoto Nishio | Japanese Foundation For Cancer Research | 12 |
| 3 | Sai‐Hong Ignatius Ou | University of California, Irvine | 11 |
| 4 | Lucio Crinò | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori | 8 |
| 5 | Anne‐Marie C. Dingemans | Erasmus MC Cancer Institute | 8 |
| 6 | Ryohei Katayama | Japanese Foundation For Cancer Research | 7 |
| 7 | Seiji Yano | Kanazawa University | 7 |
| 8 | Shirish M. Gadgeel | University of Michigan | 7 |
| 9 | Nobuyuki Yamamoto | Wakayama Medical University | 7 |
| 10 | Walter Bordogna | Roche (Switzerland) | 7 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | 2017 | 2493 | Lung Cancer Diagnosis and Treatment |
| Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial | 2017 | 925 | Lung Cancer Diagnosis and Treatment |
| Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study | 2014 | 697 | Lung Cancer Treatments and Mutations |
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial | 2015 | 641 | Lung Cancer Diagnosis and Treatment |
| CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant | 2011 | 634 | Lung Cancer Treatments and Mutations |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition and chemical structure of Alecensa?
Which organizations hold the most patents related to Alecensa?
What trend is observed in patent filings for Alecensa over recent years?
Who are the most prolific authors publishing research on Alecensa?
What patent classification areas dominate the intellectual property landscape for Alecensa?